New Insights into Migraine Treatment: CGRP Levels After Monoclonal Antibody Cessation
03 Jun 2024
Researchers have made some fascinating discoveries about the treatment of migraine. Calcitonin gene-related peptide (CGRP) has long been associated with the development of migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway, including erenumab, galcanezumab and fremanezumab, have shown promise in clinical trials and real-life studies. Initially, the European Headache Federation recommended treatment with CGRP(-R) mAbs […]
